Shots:
- Gilead signed a research partnership with Kymera to develop an oral molecular glue degrader (MGD) targeting cyclin-dependent kinase 2 (CDK2) for the treatment of breast cancer and other solid tumors
- Kymera will receive a total of up to $85M in upfront and option exercise payments and is eligible for up to $665M, plus high single-digit to mid-teens tiered royalties on net product sales under the collaboration
- Additionally, Kymera will be responsible for all research activities for the MGD CDK2. Gilead will have worldwide rights to develop, manufacture, and commercialize all MGD products resulting from the collaboration
Ref: Businesswire | Image: Gilead & Kymera | Press Release
Related News:- Verastem Oncology Reports First Patient Dosing with VS-7375 in P-I/IIa Study for KRAS G12D Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
